Dr. H. Steve White joined CURE in November of 2011. As a research advisor, Dr. White aids in the development and implementation of CURE’s strategic research program; including the unique metric-driven, collaborative team-science program that aims to find a cure or disease-modifying therapy for infantile spasms, a catastrophic encephalopathy of childhood.
In January 2016, Dr. White was appointed Chair of the Department of Pharmacy at the University of Washington School of Pharmacy. Prior to this, he was the principal investigator and scientific director of the NIH-sponsored Anticonvulsant Drug Development (ADD) Program, established in 1975 to identify novel anticonvulsant drugs using established animal seizure and epilepsy models.
Dr. White’s research is focused on understanding the factors that contribute to the initiation, propagation, and amelioration of seizure activity.
Dr. White has been the recipient of significant research funding from the National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), and he and his collaborators have published over 170 original papers pertaining to the mechanism of action and the pharmacology of antiepileptic drugs. He has been a co-organizer of two NIH-sponsored workshops on models of refractory epilepsy and epileptogenesis and currently serves on the organizing committee of the biannual Eilat Conferences on Antiepileptic Drug Development. Additionally, Dr. White has been actively engaged as a mentor for the next generation of neuroscientists and epilepsy educators and is frequently invited to speak at national and international congresses.
In 2011, Dr. White received an Honorary Doctor of Science from The University of Copenhagen Faculty of Pharmaceutical Sciences, Copenhagen, Denmark. In 2014, he was named the 2014 recipient of the Epilepsy Foundation’s Lifetime Accelerator Award, in recognition of his commitment and pioneering contributions to the field of epilepsy and seizures.